Keryx Biopharmaceuticals (NASDAQ:KERX) is set to post its quarterly earnings results after the market closes on Thursday, November 8th. Analysts expect Keryx Biopharmaceuticals to post earnings of ($0.13) per share for the quarter.
Shares of KERX stock traded up $0.16 during trading on Wednesday, hitting $2.97. 30,801 shares of the stock traded hands, compared to its average volume of 834,730. The firm has a market cap of $353.90 million, a PE ratio of -3.38 and a beta of 2.46. Keryx Biopharmaceuticals has a 52-week low of $2.74 and a 52-week high of $5.98.
Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Tuesday, July 10th. BidaskClub raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 11th. HC Wainwright set a $9.00 price target on shares of Keryx Biopharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, October 2nd. Finally, Citigroup reduced their price target on shares of Keryx Biopharmaceuticals from $4.75 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $6.25.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Read More: What is a stock buyback?
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.